Pro-PrP Regulating Agents Disrupt FLNa Binding to Inhibit Cancer Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those involving neoplastic and tumorigenic cells expressing prion protein (PrP) and filamin A (FLNa), fail to effectively inhibit adhesion, motility, migration, dispersal, and metastasis, as existing methods do not adequately target the specific interactions between pro-PrP and FLNa, which contribute to cancer cell aggressiveness.
Innovation Solution
A method involving the administration of a pro-PrP regulating agent, such as peptides or nucleic acids, that inhibit the activity or expression of pro-PrP and disrupt its binding with FLNa, using competitive inhibitors or small interfering RNAs to target cancer cells expressing pro-PrP and FLNa, thereby reducing cancer cell proliferation and invasiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then general cancer therapy is provided, but they fail to effectively inhibit adhesion, motility, migration, dispersal, and metastasis of cancer cells expressing pro-PrP and FLNa
Solution Approach 1:
The patent uses competitive inhibitor peptides as intermediary molecules that specifically bind to the pro-PrP-FLNa interaction interface. These peptides act as mediators that block the harmful interaction between pro-PrP and FLNa, thereby inhibiting cancer cell adhesion, motility, and metastasis without affecting other cellular processes. The inhibitor peptides serve as a targeted intermediary that disrupts the specific pathological interaction while leaving other cellular functions intact.
Solution Approach 2:
The invention applies local quality by designing peptides that specifically target the binding interface between pro-PrP and FLNa. The competitive inhibitors are engineered with specific amino acid sequences that match the binding domain, allowing them to selectively interfere with the pro-PrP-FLNa interaction at its precise location without affecting other protein-protein interactions in the cell. This localized targeting approach provides high specificity for the pathological interaction.
2Reliability
If pro-PrP regulating agents are administered to inhibit pro-PrP activity, then cancer cell adhesion and motility are reduced, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent extracts the essential binding interface of the pro-PrP-FLNa interaction and uses only this critical segment to design the competitive inhibitor peptides. By taking out the specific amino acid sequence from the full-length proteins and using it as a standalone peptide inhibitor, the treatment achieves high specificity with a simplified molecular structure. This extraction approach reduces the complexity of the therapeutic agent while maintaining its effectiveness in blocking the pathological interaction.
3Reliability
If competitive inhibitor peptides are used to block pro-PrP-FLNa binding, then cancer cell proliferation and invasiveness are reduced, but the specificity of peptide design requirements increase
Solution Approach 1:
The patent applies parameter changes by systematically varying the amino acid sequence of the competitive inhibitor peptides to optimize their binding affinity and specificity. The invention identifies critical amino acid residues in the pro-PrP binding domain and makes precise substitutions or modifications to enhance the inhibitor's ability to block the interaction. By carefully adjusting the sequence parameters (such as homology to the native binding domain), the peptides achieve high specificity for pro-PrP while maintaining ease of synthesis.
Data Source
AI summary
A method of inhibiting neoplastic, cancer, and/or tumorgenic cell proliferation, cell growth and motility in a subject includes administering to a cancer cell expressing Pro-PrP and FLNa a therapeutically effective amount of a Pro-PrP regulating agent.